Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Article Swipe

View

Related Concepts

fulvestrant breast cancer medicine hormone receptor internal medicine hormone endocrine system oncology cancer cancer research endocrinology estrogen receptor

Nicholas C. Turner , Mafalda Oliveira , Sacha J. Howell , Florence Dalenc , Javier Cortés , Henry Gómez , Xichun Hu , Komal Jhaveri , Petr Krivorotko , Sibylle Loibl , Serafín Morales , Meena Okera , Yeon Hee Park , Joohyuk Sohn , Masakazu Toi , Eriko Tokunaga , Samih Yousef , Lyudmila Zhukova , Elza C. de Bruin , Lynda Grinsted , Gaia Schiavon , Andrew Foxley , Hope S. Rugo ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1056/nejmoa2214131 · OA: W4378801565

Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or after previous aromatase inhibitor therapy with or without a CDK4/6 inhibitor. (Funded by AstraZeneca and the National Cancer Institute; CAPItello-291 ClinicalTrials.gov number, NCT04305496.).